Recent news coverage includes clinical progress, regulatory interactions, and financial performance updates related to Brainstorm Cell Therapeutics and its NurOwn® treatment candidate.

• Brainstorm posted a 43% EPS gain in Q2 2025, reflecting operational progress [N7].
• The company presented NurOwn survival data at the NEALS Meeting, highlighting clinical trial outcomes [N7].
• Brainstorm entered a memorandum of understanding with Pluri to support the NurOwn trial, indicating collaboration efforts [N7].
• The company received a Notice of Allowance for a patent on exosome technology, strengthening its intellectual property [N7].
• FDA meetings have provided a clear path for a planned Phase 3b trial of NurOwn in ALS, indicating regulatory engagement [N7].

The company has demonstrated clinical progress with NurOwn®, including survival data presentations and FDA meetings outlining a path for Phase 3b trials in ALS. Patent allowances and collaborations support its intellectual property and development efforts. Continued clinical and regulatory milestones could enhance the company's position in the neurodegenerative disease treatment market.

Brainstorm faces significant risks including ongoing securities and derivative litigation related to its clinical trial communications and FDA approval prospects. The company reports material weaknesses in internal controls and liquidity constraints with a low current ratio. The biotechnology sector's regulatory uncertainties and the company's history of stock price volatility add to execution risks.

Brainstorm's moat is based on its proprietary NurOwn® cell therapy technology, supported by patents including those on exosome technology, and its clinical trial data presented at scientific meetings. The company’s specialized focus on neurodegenerative diseases and ongoing regulatory interactions provide barriers to entry. However, the biotechnology sector's inherent risks, including regulatory approval challenges and competition, limit the moat's breadth.

• Legal Proceedings: The company is involved in multiple lawsuits including a securities class action and derivative actions related to NurOwn® clinical trial communications and FDA approval process, which could result in substantial costs and management distraction.
• Liquidity and Financial Condition: As of June 30, 2026, Brainstorm reported a low current ratio of 0.03 and cash ratio of 0.02, indicating potential liquidity challenges to fund ongoing operations and development.
• Internal Controls: Material weaknesses in internal control over financial reporting have been identified in prior years, posing risks to accurate financial reporting and investor confidence.
• Regulatory and Clinical Risks: The company’s success depends on regulatory approval and clinical acceptance of NurOwn®, which involves inherent uncertainties and risks.
• Stock Price Volatility and Dilution: Brainstorm’s stock price has historically been volatile, and future equity issuances may dilute existing shareholders.
• Enforcement Risks Due to Foreign Operations: With principal operations and assets outside the U.S. and foreign officers, enforcement of U.S. securities laws and judgments may be difficult.
• Cybersecurity Risks: The company acknowledges evolving cybersecurity threats and has implemented measures to mitigate risks, but incidents could impact operations.

• Brainstorm Cell Therapeutics Inc. is a publicly traded company on the OTCQB Venture Market under ticker BCLI.
• The company focuses on developing NurOwn®, a cell therapy treatment candidate for neurodegenerative diseases including ALS (amyotrophic lateral sclerosis).
• As of June 30, 2026, the company reported cash and cash equivalents of $22 million and current assets of $316 million, with current liabilities of approximately $12.385 million, resulting in a low current ratio of 0.03 and cash ratio of 0.02, indicating liquidity constraints.
• The company reported a net loss of $3.855 million for the quarter ended June 30, 2026, with basic and diluted EPS of -$0.35 per share.
• Brainstorm has ongoing legal proceedings including a securities class action and derivative lawsuits related to its NurOwn® clinical trial communications and FDA approval process, with some claims surviving motions to dismiss.
• The company has disclosed material weaknesses in internal controls over financial reporting in prior years and is subject to risks related to remediation of these weaknesses.
• Brainstorm's principal operations include a U.S. corporate headquarters in New York and leased office and laboratory space in Israel.
• The company has received a Notice of Allowance for a patent on exosome technology and has entered into a memorandum of understanding with Pluri to support the NurOwn trial.
• Brainstorm has presented survival data for NurOwn at scientific meetings and has had FDA meetings providing a path for a planned Phase 3b trial in ALS.
• The company has not paid dividends and intends to retain earnings to fund development and growth.
• The company faces risks including volatility in stock price, dilution from future equity issuances, enforcement difficulties due to foreign operations and officers, and cybersecurity risks.
• Recent news coverage includes reports on Brainstorm's EPS gains, clinical trial data, and regulatory interactions related to NurOwn® treatment development.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.